Overview

Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes

Status:
Unknown status

Trial end date:
2019-12-10

Target enrollment:

Participant gender:

Summary

The randomized, controlled clinical trial investigate the efficacy and safety of vildagliptin added to continuous subcutaneous insulin infusion in uncontrolled type 2 diabetes

Phase:

Phase 4

Details

Lead Sponsor:

The First Affiliated Hospital of Xiamen University

Treatments:

Insulin
Insulin Lispro
Insulin, Globin Zinc
Vildagliptin